Neuropsychiatric Disease and Treatment

Scope & Guideline

Unlocking New Insights in Neuropsychiatric Disease Management

Introduction

Immerse yourself in the scholarly insights of Neuropsychiatric Disease and Treatment with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN-
PublisherDOVE MEDICAL PRESS LTD
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationNEUROPSYCH DIS TREAT / Neuropsychiatr. Dis. Treat.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND

Aims and Scopes

The journal "Neuropsychiatric Disease and Treatment" aims to advance knowledge in the field of neuropsychiatry through high-quality research and clinical studies. Its scope encompasses a broad range of topics related to neuropsychiatric disorders and treatments, emphasizing both biological and psychosocial aspects of mental health.
  1. Neurodevelopmental Disorders:
    Research focusing on conditions such as Autism Spectrum Disorder and ADHD, examining their prevalence, diagnosis, and treatment strategies across diverse populations.
  2. Neuroinflammation and Neurodegeneration:
    Studies investigating the role of inflammatory processes in neurodegenerative diseases like Alzheimer's, Parkinson's, and stroke, including potential therapeutic interventions.
  3. Psychiatric Disorders and Comorbidity:
    Exploration of the interplay between psychiatric disorders, such as depression and anxiety, with chronic medical conditions, emphasizing their shared pathophysiology.
  4. Innovative Treatment Approaches:
    Research on novel therapeutic strategies, including pharmacological advancements (e.g., new antipsychotics, ketamine for depression) and non-pharmacological interventions (e.g., acupuncture, neurostimulation techniques).
  5. Cognitive and Behavioral Outcomes:
    Studies assessing cognitive functions and behavioral symptoms in various populations, particularly in relation to treatment efficacy and quality of life.
  6. Public Health and Epidemiology:
    Research highlighting the impact of socio-economic factors, health systems, and public health initiatives on mental health outcomes and treatment access.
Recent publications in "Neuropsychiatric Disease and Treatment" have highlighted several emerging themes that reflect the evolving landscape of neuropsychiatric research and treatment methodologies.
  1. Biomarkers and Precision Medicine:
    There is an increasing focus on identifying biomarkers for neuropsychiatric disorders, aiming for personalized treatment approaches that cater to individual patient profiles.
  2. Gut-Brain Axis Research:
    Emerging studies investigating the relationship between gut microbiota and neuropsychiatric conditions are gaining traction, indicating a trend towards exploring holistic and integrative treatment options.
  3. Digital Health Interventions:
    The rise of technology-assisted therapies, including mobile health applications and telepsychiatry, is becoming a prominent area of research, particularly in light of the COVID-19 pandemic.
  4. Neurostimulation Techniques:
    Innovations in non-invasive brain stimulation methods, such as transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT), are being increasingly explored for their therapeutic potential.
  5. Social Determinants of Mental Health:
    Research is increasingly addressing the impact of socio-economic and environmental factors on mental health, reflecting a broader understanding of mental health determinants.

Declining or Waning

While "Neuropsychiatric Disease and Treatment" has a diverse range of focuses, certain themes appear to be less prominent in recent publications, indicating a potential waning interest or shift in research priorities.
  1. Traditional Psychotherapies:
    There seems to be a decrease in the emphasis on traditional psychotherapy methods compared to emerging integrative approaches or pharmacological treatments, reflecting a shift towards more biologically-oriented research.
  2. Longitudinal Studies in General Populations:
    Fewer studies are being published that focus on longitudinal analyses within general populations, which may suggest a trend towards more specific clinical trials or targeted research.
  3. Animal Models in Neuroscience Research:
    While animal studies remain important, there is a noticeable decline in the number of publications utilizing these models, possibly due to a growing preference for human-centric research methodologies.
  4. Neuropsychological Assessments:
    Research centered on traditional neuropsychological testing may be declining as newer, more integrated approaches to assess cognitive and emotional health are being favored.

Similar Journals

COMPREHENSIVE PSYCHIATRY

Fostering global dialogue on psychiatric advancements.
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0010-440XFrequency: 8 issues/year

COMPREHENSIVE PSYCHIATRY is a leading peer-reviewed journal dedicated to advancing the field of psychiatry and mental health, published by W B SAUNDERS CO-ELSEVIER INC. With its Q1 designation in both Clinical Psychology and Psychiatry and Mental Health, this journal ranks impressively, holding the 9th position out of 311 in Clinical Psychology and the 27th position out of 567 in Psychiatry and Mental Health according to Scopus metrics. Since transitioning to Open Access in 2019, COMPREHENSIVE PSYCHIATRY has significantly increased its accessibility, enabling a broader audience of researchers, mental health professionals, and students to engage with cutting-edge research and clinical practices. The journal's scope encompasses a wide array of topics, including but not limited to evidence-based interventions, psychological evaluations, and the latest empirical studies in the field. As we continue to navigate the complexities of mental health in contemporary society, this journal serves as a vital resource for disseminating impactful findings and fostering collaborative discourse among scholars and practitioners globally.

Movement Disorders Clinical Practice

Advancing clinical insights for movement disorder care.
Publisher: WILEYISSN: 2330-1619Frequency: 8 issues/year

Movement Disorders Clinical Practice, published by WILEY, is an essential peer-reviewed journal dedicated to advancing the understanding and treatment of movement disorders from a clinical perspective. With an ISSN of 2330-1619, this journal serves as a vital resource for researchers, clinicians, and students engaged in neurology and clinical neuroscience. Since its inception in 2014, the journal has established itself within the medical community, currently positioned in the Q2 category for both Neurology and Neurology (Clinical), reflecting its influence and reputation. Although it does not offer open access, the journal is integral for disseminating high-quality research and clinical insights, thereby contributing significantly to improved patient care and outcomes in the field of movement disorders. Based in Hoboken, NJ, it continues to attract contributions from leading experts and aims to foster a deeper understanding and dialogue surrounding contemporary challenges and advancements in movement disorder treatment.

NEUROPHARMACOLOGY

Exploring the Intricacies of Mind and Medicine
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0028-3908Frequency: 16 issues/year

NEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.

PEDIATRIC NEUROLOGY

Advancing the Frontiers of Pediatric Neurology
Publisher: ELSEVIER SCIENCE INCISSN: 0887-8994Frequency: 12 issues/year

Pediatric Neurology, a prestigious journal published by Elsevier Science Inc, is a leading resource in the field of child neurology and developmental neurosciences. With an impressive impact factor and categorization in the Q1 and Q2 quartiles across several relevant fields, including Pediatrics, Neurology, and Developmental Neuroscience, this journal is essential for researchers and healthcare professionals focused on pediatric neurological disorders. Since its inception in 1985, it has provided a platform for high-quality research, clinical studies, and reviews that drive advancements in diagnosis, treatment, and understanding of neurological conditions in children. Although the journal does not currently offer open access, it maintains a robust reputation in the academic community, bolstered by its prominent ranking in Scopus metrics. By engaging with the latest findings published in Pediatric Neurology, readers will gain vital insights that contribute to improving pediatric healthcare outcomes in neurology and neuroscience.

Alzheimers Research & Therapy

Connecting researchers to transform Alzheimer's understanding.
Publisher: BMCISSN: Frequency: 1 issue/year

Alzheimer's Research & Therapy is a leading peer-reviewed journal published by BMC, dedicated to advancing our understanding of Alzheimer's disease and other neurodegenerative disorders. As an Open Access journal since 2009, it ensures that vital research findings are freely accessible to the global community, facilitating collaboration and innovation in the field. The journal's commitment to quality is evident in its impressive impact factor and its prestigious ranking in the Q1 quartile across multiple categories including Cognitive Neuroscience and Neurology. With a Scopus rank placing it in the top tier of both Neuroscience and Neurology disciplines, Alzheimer's Research & Therapy serves as a crucial platform for researchers, clinicians, and students who seek to contribute to the fight against Alzheimer's and related disorders. The journal covers a wide range of topics and actively encourages submissions that explore therapeutic strategies and innovative research methodologies, enriching the scientific dialogue in this vital area of health.

CHILD PSYCHIATRY & HUMAN DEVELOPMENT

Elevating Standards in Developmental and Educational Psychology
Publisher: SPRINGERISSN: 0009-398XFrequency: 6 issues/year

CHILD PSYCHIATRY & HUMAN DEVELOPMENT, published by Springer, stands at the forefront of research in the fields of developmental and educational psychology, pediatrics, perinatology, and child psychiatry. With an ISSN of 0009-398X and an E-ISSN of 1573-3327, this esteemed journal has been a vital resource for academics since its inception in 1970. Currently ranked in the Q1 category across its multiple relevant disciplines, it illustrates a significant impact with its Scopus rankings, placing it within the top 13% for pediatrics and child health and the top 18% for developmental psychology. Its comprehensive scope ensures that leading-edge studies, reviews, and discourse are accessible, contributing greatly to the understanding of mental health and developmental processes in children. With no open access option, the journal maintains a commitment to high-quality, peer-reviewed content that is invaluable for researchers, healthcare professionals, and students alike, as they strive to advance their knowledge and practices in child psychology and human development.

Progress in Neurology and Psychiatry

Exploring the frontiers of neurological and psychiatric science.
Publisher: JOHN WILEY & SONS LTDISSN: 1367-7543Frequency: 4 issues/year

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

Cognitive and Behavioral Neurology

Advancing the Frontiers of Cognitive and Behavioral Neurology
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1543-3633Frequency: 4 issues/year

Cognitive and Behavioral Neurology is a prominent peer-reviewed journal dedicated to advancing the understanding of cognitive and behavioral aspects of neurological disorders. Published by Lippincott Williams & Wilkins, this journal has established itself as a vital resource for researchers, clinicians, and students in the fields of cognitive neuroscience, neuropsychology, and psychiatry. With an ISSN of 1543-3633 and an E-ISSN of 1543-3641, it offers a robust platform for the dissemination of high-quality research, as evidenced by its positioning in the Q3 quartiles across various categories, including Cognitive Neuroscience and Psychiatry. The journal, which has been actively publishing since 2003, encourages innovative studies that explore the intersection of cognition and behavior in neurological contexts. As a vital contributor to the academic dialogue on these topics, it provides an essential archive of findings and discussions that inform clinical practice and educational approaches, reflecting its commitment to improving patient outcomes and enhancing neurological science.

Current Neuropharmacology

Transforming mental health through cutting-edge research.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-159XFrequency: 8 issues/year

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

BMC NEUROSCIENCE

Bridging Gaps in Neuroscience Knowledge for All
Publisher: BMCISSN: 1471-2202Frequency: 1 issue/year

BMC NEUROSCIENCE is a prominent open access journal dedicated to the dissemination of high-quality research within the dynamic and rapidly evolving field of neuroscience. Published by BMC, a well-respected leader in open access publishing, this journal facilitates the free exchange of knowledge since its inception in 2000. With the ISSN 1471-2202, BMC NEUROSCIENCE aims to address the diverse interests of the neuroscience community by covering a broad spectrum of topics, ranging from cellular and molecular neuroscience to general neurological studies, thus appealing to researchers, professionals, and students alike. Although it currently holds a Q4 ranking in Cellular and Molecular Neuroscience and a Q3 rank in miscellaneous Neuroscience categories, its commitment to advancing the understanding of brain function and disorders remains steadfast. The journal features a user-friendly Open Access model, ensuring that critical research findings are readily accessible to everyone, fostering collaboration and innovation in the field. As the journal continues to evolve towards its convergence years of 2024, it aspires to enhance its impact and global reach, making it a valuable resource for anyone interested in advancing neuroscience research.